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Abstract
Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical
for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective
in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development
and function of mature B cells. Shortly after its discovery, BTK was placed in the signal transduction pathway
downstream of the B cell antigen receptor (BCR). More recently, small-molecule inhibitors of this kinase have
shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies. In particular,
the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients
with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with
high-risk genetic lesions. Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was
rapidly approved for first-line treatment of patients with CLL in 2016. To date, evidence is accumulating for efficacy of
ibrutinib in various other B cell malignancies. BTK inhibition has molecular effects beyond its classic role in
BCR signaling. These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or
retention in supportive lymphoid niches. Moreover, BTK functions in several myeloid cell populations representing
important components of the tumor microenvironment. As a result, there is currently a considerable interest in BTK
inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors. Efficacy of BTK inhibition as
a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that
improve clinical responses. In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and
highlight the importance of BTK inhibition in cancer therapy.
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Background
Protein kinases represent classes of enzymes that
catalyze phosphorylation of proteins and thereby alter
their substrate’s activity or capacity to interact with other
proteins. Kinase signaling pathways represent the most
common form of reversible post-translational modifications
that control many aspects of cellular function. Aberrant ac-
tivation of protein kinases drive major hallmarks of malig-
nancies, including alterations in cellular proliferation,
survival, motility and metabolism, as well as angiogenesis
and evasion of the anti-tumor immune response [1, 2].
One such kinase that plays a crucial role in oncogenic
signaling is Bruton’s tyrosine kinase (BTK), which is crit-
ical for the survival of leukemic cells in various B cell
malignancies. BTK was initially shown to be mutated in
the primary immunodeficiency X-linked agammaglobu-
linemia (XLA) and is essential at various stages of B
lymphocyte development [3, 4]. XLA is an inherited im-
munodeficiency disease originally described by the
pediatrician Ogdon Bruton in 1952 and characterized by
recurrent bacterial infections. Due to a severe block of B
cell development in the bone marrow, XLA patients
have very low numbers of B cells in the circulation and
antibodies are almost completely absent in the serum. A
milder phenotype of the disease is present in CBA/N
mice, which harbor the loss-of-function mutation R28C
BTK [5, 6]. These mice, known as xid (X-linked
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immunodeficiency) mice, manifest only minor defects in
B cell development in the bone marrow, but instead the
differentiation and survival of mature peripheral B cells
is severely impaired [7–10]. Importantly, BTK has re-
ceived large interest since small-molecule inhibitors of
this kinase have shown excellent anti-tumor activity in
clinical studies [11, 12]. In particular, the orally adminis-
tered BTK inhibitor ibrutinib, which forms a covalent
bond with a cysteine residue in the BTK active site, was
also approved for first-line treatment of patients with
chronic lymphocytic leukemia (CLL) and small lympho-
cytic leukemia (SLL) in 2016 [13].
Shortly after its discovery as the non-receptor tyrosine
kinase defective in XLA [3, 4], BTK was placed in the
signal transduction pathway downstream of the B cell
receptor (BCR). This receptor is expressed on the B cell
surface and has the unique capacity to specifically
recognize antigens due to hypervariable regions present in
the immunoglobulin heavy (IGH) and light (IGL) chains
that together form the BCR [14]. BTK is also involved in
many other signaling pathways in B cells, including che-
mokine receptor, Toll-like receptor (TLR) and Fc receptor
signaling. Expression of BTK is not restricted to B cells, as
also cells of the myeloid lineage express BTK. In these
cells, BTK acts also downstream of TLRs and e.g. the FcεR
in mast cells [15, 16] and the FcyRI in macrophages
[17, 18]. In addition, BTK is involved in various other
pathways, including Receptor activator of nuclear factor-κB
(RANK) in osteoclasts [19], collagen and CD32 signaling in
platelets [20] and the NLRP3 inflammasome in macro-
phages and neutrophils [21]. Since myeloid cells are im-
portant components of the tumor microenvironment and
particularly tumor-associated macrophages contribute to
cancer progression [22, 23], there is currently a consider-
able interest in BTK inhibition as an anti-cancer therapy
not only in B cell leukemias but also in other hematological
malignancies and solid tumors [24–27].
In this review, we describe the importance of BTK in
multiple signaling pathways. We discuss the crucial
function of BTK in different stages of normal B cell de-
velopment. In addition, we discuss its role in oncogenic
signaling in B cell malignancies associated with genetic
events that result in increased BTK activity. We describe
clinical benefits of targeting BTK with small molecule
inhibitors in B cell malignancies. Finally, we discuss the
effects of BTK inhibitors on tumor growth in solid ma-
lignancies in the context of the function of myeloid cells
in the tumor environment.
BTK structure
BTK is one of the five members of the TEC family of non-
receptor tyrosine kinases - along with tyrosine kinase
expressed in hepatocellular carcinoma (TEC), interleukin-
2-inducible T cell kinase (ITK), resting lymphocyte kinase
(RLK) and bone marrow expressed kinase (BMX) - which
are strongly conserved throughout evolution [28]. BTK,
TEC and ITK are most similar and both contain five differ-
ent protein interaction domains (Fig. 1a). These domains
include an amino terminal pleckstrin homology (PH) do-
main, a proline-rich TEC homology (TH) domain, SRC
homology (SH) domains SH2 and SH3, as well as kinase
domain with enzymatic activity [28, 29]. BTK is essentially
cytoplasmic and is only transiently recruited to the mem-
brane through interaction of its PH domain with
phosphatidylinositol-3,4,5-triphosphate (PIP3), which is
generated by phosphatidylinositol-3 kinase (PI3K) (Fig. 1b)
[14]. BTK activation occurs in two steps upon its recruit-
ment to the cell membrane. First, BTK is phosphorylated
at position Y551 in the kinase domain by SYK or SRC
family kinases [30]. Phosphorylation of BTK at Y551 pro-
motes its catalytic activity and subsequently results in its
autophosphorylation at position Y223 in the SH3 domain
[31]. Phosphorylation at Y223 is thought to stabilize the
active conformation and fully activate BTK kinase activity
[32]. Nevertheless, a Y223F mutation did not significantly
affect the function of BTK during B cell development
in vivo, since B-cell specific transgenic expression of
Y223F-BTK could still rescue the xid phenotype of
Btk-deficient mice [33]. Therefore, the function of the
Y223 BTK autophosphorylation site remains unclear in B
cells and to date is unexplored in vivo in myeloid cells.
BTK in B cell receptor signaling
The IgM BCR is essential for survival of peripheral B cells
[34]. In the absence of BTK B cells have a high rate of
apoptosis, which correlates with strongly reduced BCR-
mediated induction of the anti-apoptotic protein Bcl-xL
[35, 36]. Upon stimulation with anti-IgM, cell size enlarge-
ment and degradation of the cyclin inhibitor p27Kip1 oc-
curs normally, indicating that BTK is not essential for
several G1 events [37]. BTK-deficient B cells enter early G1,
but not S phase of the cell cycle, because they fail to induce
cyclin D2 expression [38]. Apart from B cell survival and
proliferation, the BCR controls integrin α4β1 (VLA-4)-me-
diated adhesion of B cells to vascular cell adhesion
molecule-1 (VCAM-1) and fibronectin via BTK [39].
BCR cross-linking activates four families of non-
receptor protein tyrosine kinases and these are transduc-
ers of signaling events including phospholipase Cγ
(PLCγ), mitogen-activated protein kinase (MAPK) acti-
vation, nuclear factor kappa-light-chain-enhancer of ac-
tivated B cells (NF-кB) pathway components and
activation of the serine/threonine kinase AKT (or
protein kinase B, PKB).
The IgM BCR has a very short cytoplasmic domain and
thus cannot signal directly, but associates with the
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disulphide-linked Ig-α/Ig-β(CD79a/CD79b) heterodimers.
These transmembrane proteins contain immunoreceptor
tyrosine based activation motifs (ITAMs) in their cytoplas-
mic domain (Fig. 2). BCR engagement by antigen induces
ITAM phosphorylation by Src-family protein tyrosine
kinases such as LYN, thereby creating docking sites for
spleen tyrosine kinase (SYK)(Fig. 1b) [40]. In addition,
LYN and SYK also phosphorylate tyrosine residues in the
cytoplasmic tail of the B-cell co-receptor CD19 and/or the
adaptor protein B-cell PI3K adaptor (BCAP), which facili-
tates recruitment and activation of PI3K and the guanine
nucleotide exchange factor VAV [41, 42]. VAV further en-
hances enzymatic activity of PI3K through activation of
RAC1, a member of Rho family of GTPases [43]. PI3K
phosphorylates PIP2 to generate PIP3, which acts as a crit-
ical secondary messenger for activating downstream path-
ways. PIP3 interacts with the BTK PH-domain, resulting
in its recruitment to the plasma membrane [44].
In addition, Ig-α contains a conserved non-ITAM tyro-
sine residue, Y204, that upon activation by SYK recruits
and phosphorylates the central B cell-linker molecule
SH2-domain-containing leukocyte protein of 65 kDa
(SLP65/BLNK) [45] (Fig. 2). Hereby, the adaptor molecule
Cbl-interacting protein of 85 kD (CIN85) functions to
oligomerize SLP65 and assembles intracellular signaling
clusters for B cell activation [46]. SLP65 serves as a scaf-
fold for various signaling molecules, including BTK and its
substrate PLCγ2 [47–50]. In this micro-signalosome BTK
is activated through Y551 phosphorylation by SYK or LYN
and subsequently at Y223, as described above [30–32].
Fully activated BTK phosphorylates PLCγ2 at Y753 and
Y759, which is important for its lipase activity [51]. Acti-
vated PLCγ2 hydrolyses PIP2 into inositol triphosphate
(IP3) and diacylglycerol (DAG). IP3 regulates intracellular
calcium levels and thereby activates nuclear factor of acti-
vated T cells (NFAT) transcription, via calcineurin and cal-
modulin. DAG mediates activation of protein kinase Cβ
(PKCβ), which induces activation of several members of
the MAPK family, including extracellular signal-regulated
kinases 1 and 2 (ERK1/ERK2) and other MAPK targets,
such as Jun N-terminal kinase (JNK), p38, and NF-кB
pathway components [52] (Fig. 2). Hereby, BTK links the
BCR to NF-кB activation [53, 54].
Another important branching point is induced more
upstream in the BCR signaling cascade: in addition to
BTK, PIP3 also interacts with PH-domain of AKT,
resulting in its recruitment to the plasma membrane.
Full activation of AKT requires phosphorylation at pos-
ition T308, induced by 3-phosphoinositide-dependent
protein kinase-1 (PDK1), and at S473, phosphorylated by
mechanistic target of rapamycin (mTOR) complex 2
(See Ref [55] for an excellent review). Fully activated
AKT then returns to the cytoplasm to enable a pro-
survival signaling program that involves NFAT, forkhead
transcription factors (FOXOs) and NF-кB-mediated
pathways. Importantly, phosphorylation of AKT is posi-
tively regulated by BTK [56]. The BTK family member
TEC, which can partly compensate for BTK [57], may
a
b
Fig. 1 Domain structure of TEC kinase family members and key interacting partners of Bruton’s tyrosine kinase. a Schematic overview of the protein
structure of BTK and other TEC kinase family members. Shown are five different domains, as explained in text, the Y223 autophosphorylation site, the
Y551 phosphorylation site that activates BTK, and the C481 binding site of ibrutinib. b Schematic overview of the protein structure of key interacting
partners of BTK. PH, pleckstrin homology; TH, TEC homology; BH, BTK homology; PRR, proline rich domain; SH2/SH3, SRC homology domains 2 and 3;
Cys, cysteine-string motif
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on the other hand limit the capacity of BTK to activate
AKT [58].
Upon activation in germinal centers (GCs), B cells
can perform IGH chain class switching, by which it
changes Ig expression from one isotype to another
with different effector function, e.g. from IgM to IgG.
In this process, the IGH constant (C) region is chan-
ged, but the variable (V) region remains the same.
Interestingly, in contrast to IgM, the IgG BCR con-
tains a cytoplasmic domain of considerable length
with an Ig tail tyrosine (ITT) motif, which amplifies
signaling [59]. SYK is required for ITT phosphoryl-
ation followed by recruitment of BTK through the
adapter protein Grb2, leading to enhancement of IgG
BCR-induced calcium mobilization. This amplification
loop is thought to represent a cell-intrinsic
mechanism for rapid activation of class-switched
memory B cells.
Regulation of BTK activity and expression
Consistent with its crucial role in B cell differentiation,
proliferation and survival, proper control of BTK activity
is important for B cell homeostasis. Several mechanisms
for its regulation have been identified to date.
The recruitment of BTK to the plasma membrane
and its subsequent activation is regulated by various
phosphatases that can be recruited to the cell
membrane, similar to BTK. For example, the FcγRIIB
is an inhibitory receptor that is exclusively expressed
on B cells [60]. In contrast to the Igα/Ig-β ITAM mo-
tifs, FcγRIIB has immune tyrosine inhibitory motifs
Fig. 2 Role of Bruton’s tyrosine kinase downstream of the B cell receptor. Signaling cascade showing important events downstream of B cell receptor
(BCR). Antigen engagement by the BCR results in the formation of a micro-signalosome whereby BTK activates four families of non-receptor protein
tyrosine kinases that transduce key signaling events including phospholipase Cγ, mitogen-activated protein kinase (MAPK) activation, nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-кB) pathway components and activation of the serine/threonine kinase AKT (PKB). In addition, BTK
mediated signaling events are regulated by various phosphatases that can be recruited to the cell membrane, following crosslinking of inhibitory
receptors, e.g., FcγRIIB that is exclusively expressed on B cells and signals upon immune complex binding. See text for details
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(ITIMs) in its cytoplasmic domain [61, 62] (Fig. 2).
The binding of IgG antibodies to FcγRIIB results in
LYN-mediated phosphorylation of ITIMs and recruit-
ment of protein phosphatases such as SH2-domain
containing inositol polyphosphate 5’phosphatase-1
(SHIP1) [63–65]. SHIP1 catalyzes the dephosphoryla-
tion of PIP3 and thereby inhibits recruitment of PH-
domain containing proteins, such as BTK and PLCγ2
to the cell membrane. As a result, the downstream
increase in intracellular calcium levels is diminished.
Another phosphatase, SH2 domain containing protein
tyrosine phosphatase-1 (SHP1), has the capacity to
dephosphorylate tyrosine on BTK [65]. SHP1 acts
downstream of CD22, a lectin molecule, and the glyco-
protein CD5, both of which are on the B cell surface and
function as negative regulators of BCR signaling.
In addition, several negative regulators of BTK have
been identified. The iBTK protein directly binds to
the BTK PH domain and thereby inhibits its activity
[66]; PKCβ phosphorylates BTK on residue S180 in
TH domain, modulating its membrane localization
[67]; microRNA-185 reduces BTK mRNA levels and
thereby downregulates BTK expression [68]. Likewise,
expression of other microRNAs, including miR-210
and miR-425, significantly reduce BTK expression
[69]. In this context, it was shown that treatment of
primary CLL samples with histone deacetylase
(HDAC) inhibitors resulted in increased expression of
these miRs and decreased BTK protein. On the other
hand, BTK itself can initiate a proteasome-dependent
positive autoregulatory feedback loop by stimulating
transcription from its own promoter through a path-
way involving NF-кB [70].
BTK in other signaling pathways
Chemokine receptors
These receptors are G-protein coupled receptors that
consist of seven transmembrane spanning domains and
intracellular hetero-trimeric G-proteins composed of α,
β, and y subunits (Gα, Gβ, and Gy) [71]. The chemokine
receptors CXCR4 and CXCR5 are expressed on B cells
in different stages of their development and play import-
ant roles in trafficking, homing and homeostasis [72].
Chemokine binding to the extracellular domain of its
receptor induces conformational changes that result
in dissociation of Gα and Gβy subunits (Fig. 3a). Both
Gα and Gβy subunits can independently activate
PI3K, which results in activation of BTK, AKT and
MAPK dependent pathways [73, 74]. In addition, both
Gα and Gβy subunits can directly bind BTK via the
PH and TH domain [74, 75]. It has been shown that
the Gα subunit directly stimulates the activity of BTK
[76]. Due to its function downstream of chemokine
receptors including CXCR4 and CXCR5, BTK is im-
portant for positioning of B cells in various lymphoid
tissue compartments. This was first demonstrated by
adoptive transfer experiments with BTK-deficient B
cells, which exhibited impaired in vivo migration and
homing to lymph nodes [77].
a b c
Fig. 3 Role of Bruton’s tyrosine kinase downstream of chemokine receptors, Toll-like receptors and activating Fcγ receptors. Signaling cascade
showing important events downstream of (a) Chemokine receptors (e.g. CXCR4): upon chemokine binding to the extracellular domain Gα and
Gβy subunits can independently activate PI3K, which results in activation of BTK, AKT and MAPK-dependent pathways. b Toll-like receptors: upon
ligand recognition TLRs recruit different proteins including TIR, MYD88, IRAK1 and TIRAP/MAL, all of which interact with BTK and induce downstream
activation of the transcription factor NF-κB. c Activating Fc receptors (e.g. FcγRI): Following FcγRI cross-linking, Src-kinases, SYK, PI3K-γ and BTK are activated. In
contrast, inhibitory Fc-receptors (FcγRIIB) containing ITIM domains recruit phosphatases and reduce BTK activation (Fig. 2). See text for details
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Toll-like receptors (TLRs)
These extracellular or intracellular pattern recognition
receptors are characterized by leucine-rich repeats and
Toll/interleukin-1 receptor (TIR) domains (Fig. 3b).
TLRs, expressed in B cells or myeloid cells, recognize
structurally conserved molecules derived from bacteria
and viruses. Upon activation most TLRs recruit the
adaptor myeloid differentiation primary response 88
(MYD88) [78]. MYD88 activates interleukin-1 receptor-
associated kinase1 (IRAK1), either on its own or in com-
bination with an adaptor molecule, TIR domain contain-
ing adaptor protein (TIRAP, also known as MyD88
adapter-like (MAL)). BTK interacts with four different
proteins downstream of TLR signaling including TIR,
MYD88, IRAK1 and TIRAP/MAL) [79–81]. TLR signal-
ing induces transcription factors including NF-кB, acti-
vator protein-1 (AP-1) and interferon regulatory factor 3
(IRF3), which results in activation, proliferation,
antibody secretion, class switch recombination and
pro-inflammatory cytokine production in B cells.
Fc receptor signaling
BTK is involved in signaling of both activating
(ITAM-containing) and inhibitory (ITIM-containing)
Fc-receptors, whose balance regulates several myeloid cell
processes including activation, polarization and phagocyt-
osis (Fig. 3c) [60, 82]. BTK is rapidly activated upon FcεRI
cross-linking in mast cells [15]. In parallel to BCR
signaling, following activating Fc-receptor cross-linking,
SRC-kinases, SYK, PI3K-γ and BTK are activated [60]. In
contrast, inhibitory Fc-receptors (FcγRIIB) containing
ITIM domains recruit phosphatases and reduce BTK
activation (see above).
BTK and B cell development in the bone marrow
Even before the gene involved in XLA was identified, X-
chromosome inactivation studies showed that the defect
in XLA patients was intrinsic to the B cell lineage and
that myeloid cells had no developmental defects [83, 84].
B cells are generated from hematopoietic stem cells in
the bone marrow throughout life by the ordered re-
arrangement of IGH and IGL chain gene segments
(Fig. 4). After productive recombination of the IGH V, D
and J genes, the IGH μ protein is expressed on the cell
surface in association with the two invariant surrogate
light chain (SLC) proteins VpreB and λ5 [85, 86],as the
pre-BCR. Pre-BCR signaling marks a crucial checkpoint
(checkpoint 1) to test the functionality of the IGH μ pro-
tein (Fig. 4) [87, 88]. To date, the mechanisms that initi-
ate pre-BCR-mediated signaling are not fully resolved as
both cell-autonomous and ligand-mediated signaling has
been described [89–92]. An important function of pre-
BCR signaling is to inhibit further IGH VDJ recombin-
ation, a phenomenon known as allelic exclusion [88].
CLP Pro-B Large-
PreB
Small-
PreB
Immature Mature
Dark zone Light zone
Memory B
Plasma cells
Follicular Mantle
Marginal zone
Pre-BCR
VpreB
V 5
BCR
SHM
CSR
Cyclic re-entry
U-CLL
Pre-GC
IgM+, 
 low SHM
M-CLL
Post-GC
IgM+, 
 high SHM
MZL
MCL ABC-DLBCLFL
Pre-B ALL
T-cells
FDC
Checkpoint 1 Checkpoint 2
Check-
point 4
MM
PCNSL
WM
Transitional
Checkpoint 3
Fig. 4 Stages of B cell differentiation and associated malignancies. Model of B cell development indicating different stages of B cell differentiation and
important immune checkpoints where BTK plays a key role. Various B-cell malignancies are indicated, which are associated with abnormal BTK signaling at
distinct stages of B-cell differentiation and activation. Note that the cellular origin of U-CLL is thought to be CD5+ mature B cells. Somatic hypermutation
status of BCR and gene expression profiling indicates post-germinal center (GC) origin of M-CLL. See text for detailed information. CLP, common lymphoid
progenitor; CSR, class switch recombination; FDC, follicular dendritic cell; SHM, somatic hypermutation
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Pre-BCR signaling leads to proliferation of pre-B cells
and at the same time downregulation of SLC expression
[88]. This is important for the exit of pre-B cells from
the cell cycle to undergo the transition from large, cyc-
ling cells into small resting pre-B cells, in which IGL
chain recombination occurs. In XLA patients B cell de-
velopment is almost completely arrested at the pre-B cell
stage. Although pre-B cells expressing intracellular IGH
μ are present, they are small in size, indicating that BTK
is essential for pre-BCR-dependent proliferation. BTK-
deficient mice have only a mild pre-B cell defect,
whereby pre-B cells show impaired developmental pro-
gression into immature B-cells [9, 10]. Nevertheless, an
almost complete block is only found in mice that are
double-deficient for e.g. BTK and SLP65 or BTK and
TEC [57, 93, 94]. Interestingly SLP65-deficient mice,
which also have a mild arrest at the pre-B cell stage, de-
velop pre-B cell leukemia resembling pre-B ALL in
humans [93, 94]. In this regard, BTK cooperates with
SLP65 as a tumor suppressor independent of its kinase
activity [95, 96]. SLP65 also mediates downregulation of
SLC expression [97]. Analyses in wild-type, BTK and
SLP65 deficient pre-B cells demonstrated that pre-BCR
signaling induces IGL κ locus accessibility by functional
redistribution of enhancer-mediated chromatin interac-
tions [98]. BTK and SLP65 are important for the induc-
tion of IGL chain germ-line transcripts that are associated
with locus accessibility. Moreover, BTK-deficient mice ex-
hibit a ~ 50% reduction of IGL κ chain usage [98, 99].
Transcriptome analyses showed that BTK/SLP65deficient
pre-B cells fail to efficiently upregulate many genes in-
volved in IGL chain recombination, including Aiolos,
Ikaros, Spib, Irf4, Oct2, polymerase-μ, and Mbp-1 [98].
If IGL chain recombination is not productive or the
resulting BCR is autoreactive (checkpoint 2) (Fig. 4), devel-
oping B cells will undergo secondary IGL chain rearrange-
ments, a process termed receptor editing [100–102].
Many autoreactive B cells are lost during development to
the immature IgM+ B cell stage (central B cell tolerance),
but it has been estimated that ~ 40% of the newly
formed B cells that leave the bone marrow have
self-reactivity [92].
BTK and peripheral B cell development and
activation
Immature B cells from the bone marrow migrate to the
spleen, where selection and maturation is continued
within the transitional B cell compartment containing
T1 and T2 B cells. In mice, T1 B cells, but not T2 B
cells, are very sensitive to BCR-mediated apoptosis, indi-
cating that the T1 to T2 differentiation marks a periph-
eral tolerance checkpoint (checkpoint 3) [103, 104]. In
the absence of BTK, T2 cells do not generate survival re-
sponses and peripheral B cells are reduced by ~ 50%. As
a result, BTK-deficient B cells exhibit an impaired transi-
tion from IgMhighIgDlow into IgMlowIgDhigh mature B
cells. BTK-deficient mice lack the population of innate-
like CD5+ B-1 cells, present in the peritoneal and pleural
cavities and in small proportions in the spleen [7–9].
Consistent with the finding that these cells are import-
ant for IgM and IgG3 levels in the serum, in BTK-
deficient mice IgM and IgG3 levels in serum are severely
reduced, but the other isotypes are largely normal.
Marginal zone B cells are present in an area at the
outermost portion of the white pulp in the spleen and are
phenotypically defined as IgMhiIgDloCD21highCD23low B
cells that respond to polysaccharide antigens independ-
ently of T cell help (Fig. 4). BCR and NOTCH2 signaling
determine whether T1 B cells expressing surface
ADAM10 are committed to becoming MZ B cells in vivo
in the spleen [105, 106]. Although contradictory findings
on the numbers of MZ B cells in BTK-deficient mice have
been reported, it is clear that developing BTK-deficient
MZ B cells have a selective disadvantage [107, 108].
Upon antigen recognition, activated B cells may either
go into an extrafollicular response or develop into GC B
cells [109, 110]. In the GCs B cells strongly proliferate
and undergo somatic hypermutation (SHM) induced by
activation induced cytidine deaminase (AID). GC B cells
are selected involving follicular dendritic cells (FDCs)
and T-follicular helper (TFH) cells (checkpoint 4) based
on their antigen affinity [109]. Although BTK-deficient
mice show normal T-cell dependent responses to model
antigens, such as TNP-KLH [7, 8], there is a significant
reduction in GC B cell numbers in physiological models,
e.g. influenza virus infection [108]. In this context, it is
of note that mice expressing the constitutively active
BTK mutant E41K fail to form GCs [111, 112], whereas
overexpression of wild-type BTK induces spontaneous GC
formation [113, 114]. Consequently, BTK-overexpressing
mice develop autoimmunity involving B cell-induced
disruption of T cell homeostasis [113, 114].
BTK in B cell malignancies
BTK activity is crucial for survival and proliferation of
leukemic B cells and for their interactions with cells in
the tumor microenvironment. Below, we discuss the role
of BTK in various B cell malignancies (Fig. 4).
CLL
This is the most common leukemia in the western
world, primarily affecting the elderly, and is character-
ized by the accumulation of mature circulating IgMlow
CD5+ B cells [115]. Several genetic aberrations with
prognostic value and impact on treatment decisions in
CLL have been described. These include deletions of the
chromosomal regions 17p13 (containing the TP53 tumor
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suppressor gene), 11q23 (containing DNA damage
checkpoint protein ATM), or 13q14 (miR-15a, miR-16-1),
and trisomy of chromosome 12 [116, 117]. Furthermore,
> 80% of cases harboring del(17p) also carry TP53 muta-
tions in the remaining allele [118]. Such patients with
TP53 defects are classified as ‘high-risk’ and often respond
poorly to therapy [119]. Moreover, a significant proportion
of CLL patients carry a TP53 mutation in the absence of a
17p deletion [120, 121].
On the basis of SHM status of IGHV, CLL can be
grouped into mutated CLL (M-CLL) and unmutated CLL
(U-CLL). M-CLL have a more favorable prognosis and are
derived from post-GC B cells. The origin of U-CLL ap-
peared less clear and several cellular origins of CLL were
suggested, including MZ B cells, CD5+ B cells, and regula-
tory B cells [122–126]. Although initial gene expression
profiling indicated that M-CLL and U-CLL were quite
homogeneous and related to memory B cells derived from
T cell-dependent and T-cell independent responses, re-
spectively [123], more recent gene expression profiling
studies have provided evidence for a different origin [124].
This study by Seifert et al. shows that U-CLL derives from
unmutated mature CD5+ B cells. Moreover, it was con-
cluded that M-CLL originate from a distinct and previ-
ously unrecognized post-GC B cell subset with a CD5 +
CD27+ surface phenotype.
Several lines of evidence establish a role of chronic
BCR-mediated signaling in CLL pathogenesis [127]. (i)
Prognosis is correlated with the BCR SHM status [128];
(ii) The BCR repertoire is highly restricted [129, 130],
suggesting a role for antigenic selection in the initiation
or progression of CLL. Antigens binding to CLL BCRs
include self-antigens, such as non-muscle myosin IIA,
vimentin, apoptotic cells and oxidized low-density lipo-
protein [131–136], as well as foreign antigens (bacterial
polysaccharides and β-(1,6)-glucan, a major antigenic
determinant on fungi [132–137]); Interestingly, evidence
was provided in mice that pathogens may drive CLL
pathogenesis by selecting and expanding pathogen-
specific B cells that cross-react with self-antigens [138];
(iii) CLL cells were reported to display cell-autonomous
Ca2+ mobilization in the absence of exogenous ligands,
by virtue of recognizing a single conserved BCR-internal
epitope in the IGHV second framework region [139];
very recently, it was found that the internal epitopes rec-
ognized by CLL BCRs from distinct subgroups are dif-
ferent [140]. Moreover, the avidity of the BCR-BCR
interactions that can lead to receptor declustering influ-
ences the clinical course of the disease [139, 140].
In line with chronic BCR-mediated signaling, CLL cells
show constitutive activation of various BCR pathway as-
sociated kinases. Hereby, BTK is essential for constitu-
tively active pathways implicated in CLL cell survival,
including AKT, ERK and NF-кB, both in patient cells
and mouse models [133, 141–143]. CLL cells are
thought to interact with the tissue microenvironment
and lymph node resident CLL cells show gene expres-
sion signatures indicative of BCR activation [144, 145].
Moreover, BTK is critical for BCR- and chemokine-
controlled integrin-mediated retention and/or homing of
CLL B cells in their microenvironment [146].
Mantle cell lymphoma (MCL)
This disease results from malignant transformation of B
lymphocytes in the mantle zones surrounding GCs (Fig. 4)
and has a remarkably biased BCR repertoire [147].
Approximately 85% of the patients harbor the hallmark
chromosomal translocation t(11:14)(q13;32). This event
juxtaposes the CCND1 gene to an enhancer in the Ig
heavy chain locus [148], resulting in constitutively cyclin-
D1 expression and abnormal proliferation. In a fraction of
MCL patients lymphoma cells express the SOX11 tran-
scription factor, which is associated with minimal Ig SHM,
higher genetic instability and a more aggressive clinical
course [149, 150]. Primary MCL cells show strong expres-
sion and Y223-phosphoryation of BTK [151] and in a sub-
set of patients constitutive phosphorylation of LYN,
SLP65, SYK and PKCβ [152, 153]. Similar to CLL, the
tumor microenvironment plays an important role in MCL
pathogenesis. BTK is essential for retention of MCL cells
in lymphoid tissues, since BTK inhibition induces an
egress of malignant cells into peripheral blood [154].
Waldenström’s Macroglobulinemia (WM)
This indolent B-cell malignancy is characterized by IgM-
secreting lymphoma cells in the bone marrow. The major-
ity of WM patients have a somatic leucine to proline
substitution at position 265 of MyD88 (MyD88L265P)
[155]. This activating mutation has also been reported in
low frequencies in activated B-cell-like diffuse large B-cell
lymphoma (14%–29%) (see below), primary central
nervous system lymphoma (PCNSL; 33%), mucosa-
associated lymphoid tissue (MALT) lymphoma (9%), and
CLL (2.9%) [156–159]. The mutated MyD88L265P protein
binds phosphorylated-BTK and triggers NF-кB signaling
[160]. In addition, ~ 30% of WM patients show the
CXCR4 S338X somatic mutation, leading to enhanced
CXCL12-triggered activation of AKT and ERK [161]. In
this regard, CXCR4 and VLA-4 interactions have been
shown to regulate trafficking and adhesion of WM cells to
the bone marrow [162].
ABC-DLBCL
DLBCL is the most common form of B cell non-
Hodgkin lymphomas (B-NHLs) representing ~ 30–40%
of all cases. Patients most often present with a rapidly
growing tumor in single or multiple, nodal or extranodal
Pal Singh et al. Molecular Cancer  (2018) 17:57 Page 8 of 23
sites. Based on gene expression profiling, three major
molecular subtypes have been identified: GC B-cell-like
(GCB-DLBLCL), activated-B-cell-like (ABC-DLBCL) and
primary mediastinal B-cell lymphoma (PMBL) [163].
Whereas GCB-DLBCL and ABC-DLBCL make up the
majority of cases at roughly equal frequency, PMBL ac-
counts for up to 10% of cases of DLBCL [164]. GCB-
DLBCL tumors express many genes found in normal
GC B cells and have typically switched to an IgG BCR,
while gene expression in ABC-DLBCL, which are pre-
dominantly IgM+, resembles that of antigen-activated
plasmablasts [165, 166]. ABC-DLBCL has an inferior
clinical outcome than GCB-DLBCL with a three-year
overall survival of ~ 45% [167].
ABC-DLBCL are dependent on constitutive NF-кB
signaling for their survival and proliferation [168–170].
Approximately 50% of ABC-DLBCL harbor mutations in
CARD11 or other NF-кB pathway components, including
the MyD88L265P mutation [169–171]. In addition, ~ 20% of
patients carry an activating mutation in CD79A/B.
Consistent with a role of NF-кB downstream of the
BCR (Fig. 2), it was found that knockdown of BCR
components, CD79A/B and downstream signaling
molecules, induced cell death in ABC-DLBCL lines with
unmutated CARD11 [172]. Moreover, RNAi experiments
demonstrated that ABC-DLBCL lines are dependent on
MyD88 and its associated kinase IRAK1 for their survival
in line with NF-kB function in the TLR pathway (Fig. 3b).
In addition, SYK amplification and deletion of PTEN, a
phosphatase that dephosphorylated PIP3, are also selective
genetic alterations identified in ABC-DLBCL [173].
In contrast to ABC-DLBCL, GCB DLBCLs do not ac-
quire highly recurrent mutations in CD79A/B or NF-κB
components. Whereas ABC-DLBCL frequently respond
to BTK inhibition (see below), GC-DLBCL do not re-
spond and exhibit tonic BCR signaling that does not
affect their calcium flux, but acts primarily to activate
AKT [174]. Accordingly, forced activation of AKT res-
cued GCB-DLBCL lines from knockout of the BCR or
SYK and CD19, two mediators of tonic BCR signaling
[174]. The importance of the oncogenic AKT/PI3K path-
way in GCB-DLBCL is evident from the finding that in
~ 55% of patients the tumor suppressor phosphatase and
tensin homolog (PTEN), a negative regulator of PI3K, is
inactivated. The mechanisms of PTEN inactivation in-
clude mutation, deletion or amplification of the miR17–92
microRNA cluster that downregulates PTEN
expression [175, 176].
Primary CNS lymphoma (PCNSL), another DLBCL sub-
type, is an aggressive brain tumor that has a complete re-
sponse rate of < 40% with methotrexate-based regimens
and is subject to late recurrences. Patients showed
mutations in the MYD88, CD79B and CARD11 genes in
~ 58%, ~ 41% and ~ 13% of cases, respectively [177].
Other B cell malignancies
The hallmark of follicular lymphoma (FL), the (14;18)
translocation resulting in BCL2 overexpression, is found
in up to ~ 85% of patients. The pathogenesis of FL is
complex and involves additional cell-intrinsic genetic
changes, frequently including mutations in histone-
encoding genes (in ~ 40% of cases), the SWI/SNF com-
plex or the interconnected BCR and CXCR4 chemokine
receptor signaling pathways, as well as alterations within
the FL microenvironment [178]. The importance of BCR
and NF-κB signaling is underscored by the finding of re-
current mutations in the genes encoding CD22, SLP65/
BLNK, PLCγ2, SYK, PKCβ, BCL10, the NF-κB p100 sub-
unit and the deubiquitinating enzyme A20/TNFAIP3,
which is a negative regulator of NF-κB signaling. In
addition, the HVCN1 gene (coding for a hydrogen
voltage-gated proton channel that acts downstream of
the BCR and is downregulated in proliferating B cells) is
frequently mutated in FL. Interestingly, BTK mutations
were found that suggest activation, e.g. the L528 W mu-
tation in the kinase domain, which is associated with re-
sistance to BTK inhibition in CLL (described below),
and an in-frame deletion that also alters this amino acid
and the adjacent C527. Moreover, two loss-of-function
BTK mutations were identified, T117P and R562W,
which are also found in XLA patients, but it remains
unclear how these mutations contribute to FL
pathogenesis [178].
In multiple myeloma (MM), a malignancy of plasma
cells in the bone marrow, BTK was shown to be overex-
pressed, whereby BTK activated AKT signaling, leading
to down-regulation of P27 expression and upregulation
of key stemness genes [179, 180]. MM cells originate
from plasma cells, which do not express surface BCR,
and rely for their survival and proliferation on signals
from the microenvironment in the bone marrow. BTK
may be critical in the MM microenvironment, in
particular for secretion of cytokines and chemokines by
osteoclasts [181].
Finally, BCR and TLR are thought to be key activation
pathways in marginal zone lymphoma (MZL), often as-
sociated with chronic inflammation in the context of
autoimmunity and/or infection [182], implicating BTK
as a potential target. In this context, whole exome se-
quencing identified recurrent inactivating mutations in
Kruppel-like factor 2 (KLF2) which impeded its capacity
to suppress NF-κB activation. In addition, recurrent mu-
tations in the TLR/NF-κB pathway were found, affecting
e.g. the MYD88, TRAF3, CARD11, A20/TNFAIP3 and
CARD11 genes [183].
The BTK inhibitor ibrutinib in clinical studies
Ibrutinib (PCI-32765) is an oral irreversible BTK inhibi-
tor that covalently binds to cysteine at position 481 in
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the kinase domain and thereby blocks kinase activity
[184]. As a result BTK has lost its kinase activity, but
Y551 phosphorylation by SYK is not affected. The
in vivo effect of ibrutinib was first confirmed in a mouse
model of autoimmune disease and in dogs with spontan-
eous B-cell non-Hodgkin lymphoma, in which it induced
objective clinical responses [185].
Efficacy of ibrutinib in a clinical study was first re-
ported in patients with various relapsed/refractory B-cell
malignancies, showing clinical safety and promising dur-
able objective responses particularly in CLL and MCL
[186]. Responding patients showed sustained reduction
in lymphadenopathy, accompanied by transient rise in
absolute lymphocyte count, a phenomenon known as
lymphocytosis [186]. The next phase Ib/II multicenter
trial, with a continuous ibrutinib regimen in relapsed/re-
fractory CLL patients also showed lymphocytosis in the
first weeks of treatment, but lymphocyte counts normal-
ized or dropped below baseline after prolonged treatment
[11]. Importantly, the overall response rate was ~ 71%,
independent of clinical or genomic risk factors.
In a phase II study, patients with relapsed or refractory
MCL were treated orally with ibrutinib, resulting in a re-
sponse rate of ~ 68% [187]. It was subsequently demon-
strated that Ibrutinib was also highly active and
associated with durable responses in pretreated patients
with Waldenström’s macroglobulinemia, whereby
MYD88 and CXCR4 mutation status affected the re-
sponse [188]. Ibrutinib very rapidly received break-
through designation and was subsequently approved by
the Food and Drug Administration (FDA) for the treat-
ment of MCL, CLL and WM between November 2013
and January 2017.
In addition, ibrutinib has also been tested in other B
cell malignancies. In line with the possible role of BTK
in FL, 6 out of 16 (38%) relapsed/refractory FL patients
show response upon ibrutinib treatment [186]. In a phase
II study ibrutinib induced durable remissions in ~ 50% of
the MZL patients [189]. In a phase I study the majority
(77%) of patients with PCNSL show clinical responses to
ibrutinib [177]. Table 1 summarizes the data from current
clinical trials in various B-cell malignancies.
Several studies were performed to explain the therapeutic
mode of action of ibrutinib. In CD40- or BCR-activated
CLL cells, ibrutinib reduced survival by abrogating down-
stream pathways including ERK, PI3K and NF-кB [141].
Ibrutinib inhibited migration of CLL cells towards chemo-
kines such as CXCL12 and CXCL13, suggesting that treat-
ment inhibits homing and retention of malignant cells in
their survival niches [77]. Ibrutinib was also found to
Table 1 Clinical trials with BTK inhibitors in B cell malignancies
Patient population Therapeutic regimen Phase Efficacy Ref
R/R CLL Ibrutinib Ib/II ORR (71%), PR(20%) [11]
R/R CLL Ibrutinib III ORR (63%) [248]
TN CLL Ibrutinib Ib/II ORR (85%), CR(26%) [199]
TN CLL Ibrutinib III ORR (86%), CR(4%) [13]
R/R MCL Ibrutinib II ORR (68%), CR(21%) [187]
R/R MCL Ibrutinib III ORR (72%), CR(19%) [249]
R/R WM Ibrutinib II ORR(91%), Major response (73%) [188]
R/R ABC-DLBCL Ibrutinib II ORR (37%) [196]
R/R CLL Ibrutinib-Rituximab II ORR (95%), CR(8%) [250]
R/R CLL Ibrutinib-bendamustine-rituximab III ORR (83%), CR(10%) [251]
R/R MCL Ibrutinib-Rituximab II ORR (88%), CR(44%), PR(44%) [252]
R/R CLL Acalabrutinib I/II ORR(95%) [12]
R/R Acalabrutinib II ORR (81%), CR (40%), PR(41%) [219]
R/R CLL ONO/GS-4059 I ORR(96%) [222]
R/R MCL ONO/GS-4059 I ORR(92%) [222]
R/R non-GCB DLBCL ONO/GS-4059 I ORR(92%) [222]
R/R CLL BGB-3111 I ORR(90%) [221, 253]
R/R MCL BGB-3111 I ORR(80%) [253]
R/R MZL Ibrutinib II ORR(51%) [254]
R/R FL Ibrutinib I ORR(38%) [186]
CLL Chronic Lymphocytic leukemia, MCL Mantle cell lymphoma, WM Waldenström’s Macroglobulinemia, ABC-DLBCL Activated B-cell Diffuse large B cell Lymphoma,
MZL Marginal zone lymphoma, FL Follicular lymphoma, R/R relapsed or refractory, TN treatment-naïve, ORR overall response rate, CR complete response, PR partial
response, Major response: complete response or at least 50% reduction in serum IgM levels
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reduce secretion of BCR-dependent chemokines CCL3 and
CCL4 [142]. Another key effect was that it inhibited integ-
rin α4β1-mediated adhesion of CLL cells to fibronectin
and VCAM1 [146] and thus interaction with the tumor
microenvironment [146]. Therefore, ibrutinib apparently
works by a dual mechanism, by inhibiting intrinsic B cell
signaling pathways to compromise their proliferation and
survival as well as by disrupting tumor-microenvironment
interactions. Importantly, both in CLL and MCL ibrutinib
treatment induces a redistribution lymphocytosis, a transi-
ent rise of leukemic cells in the circulation and a concomi-
tant rapid reduction of these cells at the affected tissue
sites. In contrast to classical cytotoxic chemotherapy, ibru-
tinib does not cause tumor lysis syndrome, which is a com-
mon complication of cancer therapy because of metabolic
disturbances when large numbers of tumor cells die
quickly. Therefore, most likely the displacement of B cells
from nurturing tissue niches because of inhibition of
integrin-mediated retention of leukemic cells, is an import-
ant mechanism of action of ibrutinib, rather than robust in-
hibition of survival of malignant B cells [190]. As a result,
leukemic cells undergo ‘death by neglect’, because their
mobilization induces ‘homelessness’ (anoikis), a form of
programmed cell death [191, 192].
Despite impressive clinical success of ibrutinib, its
curative potential in B cell malignancies is not estab-
lished yet, as ibrutinib is often prescribed as life-long
therapy. Importantly, continuous therapy may lead to se-
lection or outgrowth of resistant clones, as described in
a subset of patients who relapse upon ibrutinib therapy.
Two important therapy-associated resistance mecha-
nisms have been identified, involving BTK C481S muta-
tion (the site of action of Ibrutinib) or activating
mutations in PLCy2 (R665W, S707Y and L845F) [193,
194]. Recently another BTK mutation, T316A in the
SH2 domain, was described, as well as clonal evolution
underlying leukemia progression in patients with
ibrutinib-relapsed CLL [195]. In addition, missense mu-
tation within the coiled-coil domain of CARD11
(R179Q) have been shown to promote BTK-independent
activation of NF-κB and thus ibrutinib resistance in
DLBCL, MCL and PCNSL [177, 196, 197]. Furthermore,
an activating mutation in BTK (L528 W) that confers re-
sistance to ibrutinib treatment has been found in CLL
and FL [178, 198].
In clinical trials the adverse events were mostly limited
to grade 1 or 2 in severity, but in some cases side-effects
led to discontinuation of the therapy [199–201]. Because
ibrutinib treatment has a considerable high risk of bleeding
in treated patients, concomitant anti-coagulation (~ 11%)
and antiplatelet (~ 34) use is common and ~ 3% of the pa-
tients were reported to have major bleeding events [202].
Atrial fibrillation has been reported in up to 16% of pa-
tients taking ibrutinib, whereby stroke prevention poses a
challenge because of the increased bleeding risk. Therefore,
close monitoring is recommended, especially during the
first 6 months of ibrutinib therapy [203]. Although the oc-
currence of atrial fibrillation might possibly be related to
inhibition of the BTK-regulated PI3K/AKT pathway in car-
diac myocytes [204], the mechanisms involved remain
largely unidentified.
Three year follow-up of ibrutinib-treated CLL patients
showed that prolonged treatment was associated with
improvement in response quality (the ORR increased to
> 90%) and durable remission, while toxicity including
cytopenia, fatigue, and infection diminished. Moreover,
progression remains uncommon [205]. Findings from
the longest follow-up reported to date, evaluating up to
5 years of ibrutinib in CLL patients, show that it is rela-
tively safe and effective, with ~ 89% of treatment-naïve
and relapsed patients experiencing a response to the
therapy [206].
Part of the toxicities and side effects of ibrutinib can be
explained by its non-specific nature: ibrutinib is not an ex-
clusive inhibitor of BTK and off-target inhibition includes
kinases that contain a cysteine residue aligning with Cys-
481 in BTK. These include other TEC-family kinases (ITK,
BMX, TEC), as well as epidermal growth factor receptor
(EGFR), T-cell X chromosome kinase (TXK) and Janus
Kinase 3 (JAK3) [12, 185, 207]. In this context, it is of note
that the bleeding risk in patients receiving ibrutinib was
thought to relate to off-target inhibition of TEC [12]. BTK
is expressed in platelets where it is important for signaling
via the collagen receptor glycoprotein VI (GPVI); platelets
from XLA patients display diminished aggregation, dense
granule secretion and calcium mobilization in response to
collagen and C-reactive protein [208]. Nevertheless, XLA
patients do not have an increased risk of bleeding [209].
Findings by Bye et al. indicated that both BTK and TEC –
although required for GPVI-mediated platelet aggregation
– are redundant for platelet adhesion to collagen and
thrombus formation [210]. Rather, ibrutinib but not the
more selective BTK inhibitor acalabrutinib (see below) in-
hibits SRC family kinases that have a critical role in platelet
function [210]. These findings explain why in contrast to
ibrutinib, treatment with acalabrutinib was not associated
with major bleeding events [12].
A recent systematic review of infectious events with
ibrutinib in the treatment of B cell malignancies provided
evidence for infection-related complications in ~ 50% of
patients taking ibrutinib, whereby ~ 20% of patients devel-
oped pneumonia due to opportunistic pathogens [211].
Hereby, data suggest that these events may involve inhib-
ition of both BTK and its closely related family member
ITK. On the other hand, it was shown that ibrutinib treat-
ment increased the in vivo persistence of both CD4+ and
CD8+ activated T cells and diminished the immune-
suppressive properties of CLL cells. As these effects were
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not seen with more specific BTK inhibitor acalabrutinib
that lacks ITK inhibitory activity (see below), it was con-
cluded that the T cell expansion is unlikely to be caused
by BTK inhibition [212]. Rather, ibrutinib treatment of ac-
tivated T cells diminishes activation-induced cell death by
targeting ITK, a finding also reported in murine models of
ITK deficiency. However, both inhibitors reduced the ex-
pression of the inhibitory co-receptors programmed cell
death protein 1 (PD-1) and cytotoxic T-lymphocyte-
associated protein 4 (CTLA4) on T cells, as well as expres-
sion of the immunosuppressive molecules CD200, B- and
T-lymphocyte attenuator (BTLA) and IL-10 by CLL cells
[212]. Therefore, ibrutinib likely diminishes the immune-
suppressive properties of CLL cells through both
BTK-dependent and ITK-dependent mechanisms.
Inhibition of BTK and ITK with ibrutinib was shown
to be effective in the prevention of chronic graft-versus-
host (GvH) disease following allogeneic hematopoietic
stem cell transplantation (SCT) in several mouse models
[213, 214]. Accordingly, also studies in patients with re-
lapsed CLL following SCT support that ibrutinib aug-
ments the GvH versus-leukemia (GVL) benefit likely
through ITK inhibition [215]. In particular, it was shown
that ibrutinib selectively targeted pre–germinal B cells
and depleted Th2 helper cells, whereby these effects per-
sisted after drug discontinuation.
Taken together, these findings provide a rationale for
combination immunotherapy approaches with ibrutinib
in CLL and other cancers.
Ibrutinib in combination therapies and second
generation BTK inhibitors
The finding of ibrutinib resistance, together with multiple
modes of action and the microenvironmental dependence
of B-cell malignancies, has fueled the development of novel
combination strategies. With the aim to achieve deeper re-
missions within a short treatment time, many ibrutinib
combination therapies are currently considered (Table 2).
Hereby, ibrutinib treatment forces egress of malignant B
cells out of their protective niches into circulation, where
they become vulnerable to direct cytotoxic activity of either
chemotherapy, an inhibitor of the pro-survival protein Bcl-
2, or antibody mediated cytotoxicity (ADCC) of anti-CD20
antibody therapy.
Side-effects associated with off-target kinase inhibition
may limit the use of ibrutinib as therapeutic agent (as
discussed above). Ibrutinib can antagonize rituximab-
induced ADCC due to inhibition of its family member
ITK in NK cells, further limiting its use in combination
regimens [216]. Therefore, many efforts have focused on
developing highly selective BTK inhibitors, of which
three have reached advanced stages of clinical
development [217].
Acalabrutinib (ACP-196)
This highly selective irreversible BTK inhibitor has signifi-
cantly less off-target kinase activity [207]. Acalabrutinib
also binds C481 and lacks irreversible targeting to alterna-
tive kinases, such as EGFR, ITK, TXK, SRC family kinases
and JAK3. The first pre-clinical study in canine models of
Non-Hodgkin B-cell lymphoma demonstrated enhanced
in vivo potency compared to ibrutinib [218]. In a phase I/
II clinical trial in patients with relapsed/refractory CLL the
overall response rate was ~ 95% and in patients with
del(17)(p13.1) this was 100%, with a median follow-up up
~ 14 months [12]. No dose-limiting toxicities, episodes of
atrial fibrillation, or bleeding-related events have been re-
ported to date. To investigate the superiority of either in-
hibitor, a phase III trial for direct comparison of ibrutinib
with acalabrutinib in R/R CLL patients is currently on-
going (NCT02477696). Additionally, in a phase II trial in
patients with relapsed/refractory MCL, acalabrutinib in-
duced an overall response of ~ 81% with ~ 40% patients
achieving a complete response [219]. This led to acceler-
ated FDA approval of acalabrutinib in MCL [220].
BGB-3111
Another selective inhibitor of BTK kinase activity with su-
perior oral bioavailability and higher selectivity than ibruti-
nib is BGB-3111, which was shown to inhibit proliferation
of several MCL and DLBCL cell lines. Due to weaker ITK
inhibition, BGB-3111 was at least 10-fold weaker than
ibrutinib in inhibiting rituximab induced ADCC. When 45
CLL patients were treated on a phase I/II study, therapy
was well tolerated and was associated with a response rate
of ~ 90% after a follow-up of 7.5 months and no cases of
disease progression or Richter’s transformation [221] (see
also Table 1).
Ono/GS-4059
In vivo efficacy of this compound was initially described
in an ABC-DLBCL xenograft model and in vitro anti-
proliferative effects in DLBCL, FL, MCL and CLL cell
lines were described [222]. Early-phase clinical trial data
in patients with several B-cell malignancies include clin-
ical responses in patients with high-risk CLL genetics
(Table 1).
Role of BTK in the tumor microenvironment
Inhibition of BTK has now also extended into the field
of solid tumors, following insights into the role of BTK
in various cells of the tumor microenvironment and in
non-hematological tumor cells when ectopically
expressed. An understanding of the diverse roles of BTK
in non-lymphocytic cells will be pivotal in the develop-
ment of novel treatment combinations for haematopoi-
etic and solid tumors.
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BTK is involved in TLR- and Fc-receptor mediated ac-
tivation, maturation, migration and survival of myeloid
cells [223, 224]. However, the role of BTK identified is
dependent on cell type investigated, the nature of acti-
vating stimuli, the model used (in vivo or in vitro) and
the species investigated, i.e. mouse or human. Analyses
in various mouse models and in vitro studies with mye-
loid cells from XLA-patients clearly implicate BTK in
TLR4/8/9-signaling, and possibly others [79, 225–227].
However, data are often conflicting, e.g. TLR8-induced
IL-6 production by BTK-deficient DCs were reported to
be impaired [226], enhanced [228], or unaffected [229].
Also TLR4/7/8-induced TNFα was reported to be re-
duced [226, 229] or enhanced [228].
Of further relevance in the context of the tumor
microenvironment is the polarization status of macro-
phages, with M1 macrophages displaying a pro-
inflammatory anti-tumor phenotype and M2 macro-
phages being immunosuppressive [22]. Whereas one
study indicated an M2-skewing of BTK-deficient macro-
phages [230], recently in a pancreatic cancer mouse
model an M1-skewing of intratumoral macrophages was
found following ibrutinib treatment [231]. In contrast,
ibrutinib induced M1 to M2-skewing of nurse-like cells,
which show properties of tumor-associated macro-
phages, accompanied by impaired phagocytosis, in-
creased IL-10 production mediating pro-survival signals
in CLL [232]. It remains unknown what causes these in-
congruences in BTK-dependent myeloid polarization,
however it is conceivable that the different roles of BTK
in a complex ecology of tumor-infiltrating cells and the
limited specificity of ibrutinib contribute to the conflict-
ing findings.
In solid tumors, chronic deposition of immune com-
plexes foster carcinogenesis due to chronic inflamma-
tion, angiogenesis and M2 macrophage polarization in
response to activating Fc-receptor ligation on myeloid
cells [231, 233, 234]. Interestingly, inhibiting BTK during
Fc-receptor stimulation of macrophages in vitro using
Ibrutinib prevented M2-skewing [231].
Granulocytes and their immature immune-suppressive
counterparts, myeloid derived suppressor cells (MDSC),
are strongly implicated in tumor progression, rendering
them important candidates for therapy [235]. Although
loss of BTK in XLA neutrophils does not impair func-
tional TLR responses [236], the numbers of circulating
granulocytes are reduced in XLA-patients and BTK-
deficient mice [237–239]. Moreover, BTK-deficient neu-
trophils manifest increased sensitivity to apoptosis, de-
creased maturation, differentiation, trafficking and
impaired functionality including reactive oxygen species
(ROS) production [238–241]. Likewise, ibrutinib treat-
ment inhibited the generation, migration, TNFα and
ROS-production of MDSCs both in vitro and in solid
tumor mouse models [242]. Ibrutinib treatment partially
alleviated MDSC-mediated CD8+ T-cell suppression and
enhanced anti-PD-L1 therapy efficacy in a breast cancer
model. BTK inhibition in granulocytes and MDSCs in
solid tumors may therefore be important in the develop-
ment of effective combination therapies.
BTK inhibition in solid malignancies
Ectopic BTK expression has been observed in various
solid tumors, whereby evidence is accumulating for its
involvement in oncogenesis [24–27]. These pre-clinical
findings have led to the initiation of several early phase
I/II clinical trials in which BTK inhibition monotherapy
is evaluated in advanced ovarian, colorectal, prostate and
brain cancer patients(Table 3).
Also in BTK-negative solid tumors that do not express
BTK, its inhibition may hold promise as multiple cell
types in the tumor microenvironment are regulated by
BTK. Inhibition of BTK in pre-clinical models of pancre-
atic cancer, breast cancer and BTK-negative colon can-
cer have shown only marginal improvement of survival
as monotherapy, but when combined with chemo- or
immunotherapy, survival was greatly enhanced [231,
242, 243]. This has sparked the emergence of several tri-
als investigating the safety and efficacy of ibrutinib or
acalabrutinib, in combination with conventional PD-1/
PD-L1 checkpoint inhibition therapy (Table 3).
Given that ibrutinib shows off-target inhibition of
JAK3, ITK and EGFR [185, 207], it can be used to
target oncogenic pathways other than BTK in tumor
cells and as a T-cell modulator in combination im-
munotherapy [243–246]. Hereby, ibrutinib treatment
increased cellular persistence and decreased expres-
sion of co-inhibitory surface molecules on Chimeric
antigen receptor (CAR) T cells in models of CLL and
MCL [245, 246]. Whether in these studies ibrutinib
acts on ITK in (CAR) T cells, on BTK in the malig-
nant cells or other kinases remains undetermined.
Paradoxically, inhibiting ITK in T cells may be effica-
cious in cancer, as this may enhance Th1-skewing of
CD4+ T-cells and thereby improved memory forma-
tion and functionality of CD8+ T-cells, potentially
leading to improved anti-tumor immunity [243, 247].
These potentially beneficial off-target effects of ibruti-
nib may be lost in the highly specific BTK-inhibitors
that are currently being evaluated.
Conclusions
Targeting of BTK, which has a central role in several
signaling pathways in B cells, particularly the BCR,
has shown impressive efficacy as therapeutic option
for various B cell malignancies in clinical trials. Much
progress has been made in recent years in defining
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the complex mechanisms of action of BTK inhibition.
These involve intrinsic signaling pathways in leukemic
cells that are central to cellular survival, proliferation
and - most importantly - retention in supportive mi-
croenvironments. Moreover, BTK inhibition shows
promise as a therapy that influences crucial immune
cells in the tumor microenvironment. Because data
from BTK-deficient or inhibitor-treated myeloid cells
in the context of cancer are scarce, it is not clear
whether BTK inhibition by e.g. ibrutinib is based on
its specificity for BTK in particular myeloid cells and/
or due to off-target effects in signaling pathways in
CD4+ or CD8+ T cells. Of note, because in CLL ibru-
tinib treatment diminished the immunosuppressive
properties of malignant cells through BTK-dependent
and BTK-independent mechanisms (probably via ITK
inhibition) [212], it will be interesting to observe
whether the same level of anti-tumor efficacy is main-
tained by specific BTK inhibition alone. It is very well
conceivable that for particular malignancies it may be
advantageous to use BTK inhibitors that show
additional specificity for related kinases.
Although the efficacy of BTK inhibition as a single
agent therapy is strong, it has been shown that resist-
ance may develop and now a broad range of studies
focus on development of effective combination ther-
apies to improve clinical responses. The identification
of differences in efficacy and toxicity profiles between
available BTK inhibitors awaits direct comparative
studies. In this context, design of treatment strategies
will depend on detailed analyses of clinical responses,
resistance development, toxicity and quality of life for
individual BTK inhibitors in combination therapies in
relation to the various malignancies and patient
subgroups.
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Table 3 Clinical trials with BTK-inhibitors in solid tumors
BTK-inhibitor Tumor Type Treatment combination Phase Trial Status NCT#
Ibrutinib Pancreatic Cancer nab-paclitaxel and gemcitabine ll/lll Ongoing, Not Recruiting NCT024B6668
Ibrutinib Pancreatic Cancer nab-paclitaxel and gemcitabine I Recruiting NCT02562898
Ibrutinib Renal/Urethelial/Gastric/Colorectal Cancer chemotherapy/small molecule Ib/II Recruiting NCT02599B24
Ibrutinib HER2/MYC + Oesophageal Cancer I Recruiting NCT02884453
Ibrutinib EGFR + Non-small Cell Lung Cancer (NSCLC) I/ll Ongoing, Not Recruiting NCT02321540
Ibrutinib NSCLC/Breast Cancer/Pancreatic Cancer Durvalumab (anti-PD-L1) I/ll Completed NCT02403271
Ibrutinib Pancreatic Neuro-endocrine tumors (pNET)
/metastatic Carcinoid
II Recruiting NCT02575300
Ibrutinib Stage IV Cutaneous Melanoma II Recruiting NCT02581930
Ibrutinib Metastatic Renal Cancer Nivolumab (anti-PD-L1) lb./ll Recruiting NCT02899078
Ibrutinib Localized Prostate Cancer I/II Recruiting NCT02643667
Acalabrutinib Advanced/Metastatic Pancreatic Cancer Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02362048
Acalabrutinib Recurrent Ovarian Cancer Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02537444
Acalabrutinib Glioblastoma lb/ll Recruiting NCT02586857
Acalabrutinib NSCLC Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02448303
Acalabrutinib Head and Neck Squamous Cell Carcinoma
(HNSCC)
Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02454179
Acalabrutinib Platinum-resistant Urethelial (Bladder) Cancer Pembrolizumab (anti-PD-L1) II Ongoing, Not Recruiting NCT02351739,
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